BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-8. [PMID: 17589190 DOI: 10.1097/QAD.0b013e328216f441] [Cited by in Crossref: 196] [Cited by in F6Publishing: 222] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Getu A, Wolde HF, Animut Y, Kibret AA. Incidence and predictors of Tuberculosis among patients enrolled in Anti-Retroviral Therapy after universal test and treat program, Addis Ababa, Ethiopia. A retrospective follow -up study. PLoS ONE 2022;17:e0272358. [DOI: 10.1371/journal.pone.0272358] [Reference Citation Analysis]
2 Dowdy DW, Behr MA. Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings? Lancet Infect Dis 2022:S1473-3099(22)00153-0. [PMID: 35526558 DOI: 10.1016/S1473-3099(22)00153-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Tancredi MV, Sakabe S, Waldman EA. Mortality and survival of tuberculosis coinfected patients living with AIDS in São Paulo, Brazil: a 12-year cohort study. BMC Infect Dis 2022;22:223. [PMID: 35246066 DOI: 10.1186/s12879-022-07232-6] [Reference Citation Analysis]
4 González-Duran JA, Plaza RV, Luna L, Arbeláez MP, Deviaene M, Keynan Y, Rueda ZV, Marin D. Delayed HIV treatment, barriers in access to care and mortality in tuberculosis/HIV co-infected patients in Cali, Colombia. Colomb Med (Cali) 2021;52:e2024875. [PMID: 35571589 DOI: 10.25100/cm.v52i3.4875] [Reference Citation Analysis]
5 Amoroso M, Langgartner D, Lowry CA, Reber SO. Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents. Int J Mol Sci 2021;22:12938. [PMID: 34884743 DOI: 10.3390/ijms222312938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Liou BH, Cheng CN, Lin YT, Lin YJ, Chuang YC, Lin KY, Liu WC, Lin SW, Kuo CH, Sun HY, Hung CC. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. J Int AIDS Soc 2021;24:e25844. [PMID: 34822220 DOI: 10.1002/jia2.25844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lwevola P, Izudi J, Kimuli D, Komuhangi A, Okoboi S. Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review. J Clin Tuberc Other Mycobact Dis 2021;25:100269. [PMID: 34504952 DOI: 10.1016/j.jctube.2021.100269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Maokola WM, Ngowi BJ, Mahande MJ, Todd J, Robert M, Msuya SE. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania. PLoS One 2021;16:e0254082. [PMID: 34255776 DOI: 10.1371/journal.pone.0254082] [Reference Citation Analysis]
9 van de Water BJ, Meyer TN, Wilson M, Young C, Gaunt B, le Roux KW. TB prevention cascade at a district hospital in rural Eastern Cape, South Africa. Public Health Action 2021;11:97-100. [PMID: 34159070 DOI: 10.5588/pha.20.0055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Opollo V, Sun X, Lando R, Miyahara S, Torres TS, Hosseinipour MC, Bisson GP, Kumwenda J, Gupta A, Nyirenda M, Katende K, Suryavanshi N, Beulah F, Shah NS. The effect of TB treatment on health-related quality of life for people with advanced HIV. Int J Tuberc Lung Dis 2020;24:910-5. [PMID: 33156757 DOI: 10.5588/ijtld.19.0716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis 2020;24:396-402. [PMID: 32317063 DOI: 10.5588/ijtld.18.0740] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Shin H, Jo Y, Chaisson RE, Turner K, Churchyard G, Dowdy DW. Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV. J Int AIDS Soc 2020;23:e25629. [PMID: 33107219 DOI: 10.1002/jia2.25629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Azanaw MM, Derseh NM, Yetemegn GS, Angaw DA. Incidence and predictors of tuberculosis among HIV patients after initiation of antiretroviral treatment in Ethiopia: a systematic review and meta-analysis. Trop Med Health 2021;49:18. [PMID: 33632342 DOI: 10.1186/s41182-021-00306-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Komba FF, Frumence G. Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania. Pan Afr Med J 2021;38:197. [PMID: 33995803 DOI: 10.11604/pamj.2021.38.197.26752] [Reference Citation Analysis]
15 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Dorjee K, Topgyal S, Tsewang T, Tsundue T, Namdon T, Bonomo E, Kensler C, Lhadon D, Choetso T, Nangsel T, Dolkar T, Tsekyi T, Dorjee C, Phunkyi D, Sadutshang TD, Paster Z, Chaisson RE. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment. PLoS Med 2021;18:e1003502. [PMID: 33465063 DOI: 10.1371/journal.pmed.1003502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kato‐maeda M, Luetkemeyer A, Small PM. Tuberculosis Associated with HIV Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2021. [DOI: 10.1128/9781555817138.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Legese H, Degefa H, Gebrewahd A, Gebremedhin H. Utilization of isoniazid prophylaxis therapy and its associated factors among HIV positive clients taking antiretroviral therapy at Fre Semaetat primary hospital, Hawzien districts, Tigrai, Northern Ethiopia. Trop Dis Travel Med Vaccines 2020;6:11. [DOI: 10.1186/s40794-020-00106-2] [Reference Citation Analysis]
19 Sharan R, Kaushal D. Vaccine strategies for the Mtb/HIV copandemic. NPJ Vaccines 2020;5:95. [PMID: 33083030 DOI: 10.1038/s41541-020-00245-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 van Halsema CL, Okhai H, Hill T, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. AIDS 2020;34:1813-21. [PMID: 32501837 DOI: 10.1097/QAD.0000000000002599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Mengesha Y, Ahmed M. Assessment of Isoniazid Preventive Therapy Outcome Among People Living with HIV in a Referral Hospital, Northeast Ethiopia. Integr Pharm Res Pract 2020;9:127-33. [PMID: 32983945 DOI: 10.2147/IPRP.S268924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Romanowski K, Rose C, Cook VJ, Sekirov I, Morshed M, Djurdjev O, Levin A, Johnston JC. Effectiveness of Latent TB Screening and Treatment in People Initiating Dialysis in British Columbia, Canada. Can J Kidney Health Dis 2020;7:2054358120937104. [PMID: 32655871 DOI: 10.1177/2054358120937104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Tchakounte Youngui B, Coffie P, Messou E, Poda A, Fortes Deguenonvo L, Hawerlander D, Minga A, Balestre E, Dabis F, Marcy O. Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infect Dis 2020;7:ofaa203. [PMID: 32607387 DOI: 10.1093/ofid/ofaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Boffa JM, Fisher DA, Mayan MJ, Sauve RS, Williamson TS. Effectiveness of Isoniazid Preventive Therapy to Reduce Tuberculosis Incidence in the Context of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2020;84:e14-e17. [DOI: 10.1097/qai.0000000000002339] [Reference Citation Analysis]
25 Bares SH, Swindells S. Latent Tuberculosis and HIV Infection. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00726-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Tweya H, Feldacker C, Mpunga J, Kanyerere H, Heller T, Ganesh P, Nkosi D, Kalulu M, Sinkala G, Satumba T, Phiri S. The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi. J Int AIDS Soc 2019;22:e25240. [PMID: 31038836 DOI: 10.1002/jia2.25240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med 2019;40:839-48. [PMID: 31731988 DOI: 10.1016/j.ccm.2019.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Takarinda KC, Harries AD, Mutasa-Apollo T, Sandy C, Choto RC, Mabaya S, Mbito C, Timire C. Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. BMJ Open 2020;10:e034721. [PMID: 32265241 DOI: 10.1136/bmjopen-2019-034721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat 2020;2020:7025738. [PMID: 32411454 DOI: 10.1155/2020/7025738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, Ruff A. Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia. Int J Tuberc Lung Dis 2019;23:371-7. [PMID: 30871669 DOI: 10.5588/ijtld.18.0378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis 2018;22:1435-42. [PMID: 30606315 DOI: 10.5588/ijtld.18.0370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kim HY, Dowdy DW, Martinson NA, E Golub J, Bridges JFP, Hanrahan CF. Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey. J Int AIDS Soc 2018;21:e25143. [PMID: 29972628 DOI: 10.1002/jia2.25143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
34 Muyaya LM, Musanda EM, Tamuzi JL. Human immunodeficiency virus-associated tuberculosis care in Botswana: evidence from a real-world setting. BMC Infect Dis 2019;19:767. [PMID: 31477055 DOI: 10.1186/s12879-019-4401-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wong NS, Leung CC, Chan KCW, Chan WK, Lin AWC, Lee SS. A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients. Sci Rep 2019;9:10093. [PMID: 31300686 DOI: 10.1038/s41598-019-46570-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
36 Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, Corbett EL, Chaisson RE, Dowdy DW. Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi. Int J Tuberc Lung Dis 2018;22:371-7. [PMID: 29562983 DOI: 10.5588/ijtld.16.0836] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
37 Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang WH. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open 2019;9:e029058. [PMID: 31147370 DOI: 10.1136/bmjopen-2019-029058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Geremew D, Endalamaw A, Negash M, Eshetie S, Tessema B. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infect Dis 2019;19:405. [PMID: 31077133 DOI: 10.1186/s12879-019-4031-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
39 Charan J, Goyal JP, Reljic T, Emmanuel P, Patel A, Kumar A. Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. Pediatr Infect Dis J 2018;37:773-80. [PMID: 29280783 DOI: 10.1097/INF.0000000000001879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 2018;78:54-61. [PMID: 29406428 DOI: 10.1097/QAI.0000000000001641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
41 Tiruneh G, Getahun A, Adeba E. Assessing the Impact of Isoniazid Preventive Therapy (IPT) on Tuberculosis Incidence and Predictors of Tuberculosis among Adult Patients Enrolled on ART in Nekemte Town, Western Ethiopia: A Retrospective Cohort Study. Interdiscip Perspect Infect Dis 2019;2019:1413427. [PMID: 31186628 DOI: 10.1155/2019/1413427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
42 Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 154] [Cited by in F6Publishing: 166] [Article Influence: 51.3] [Reference Citation Analysis]
43 Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 2018;77:405-12. [PMID: 29239900 DOI: 10.1097/QAI.0000000000001610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yirdaw KD, Teklu AM, Mamuye AT, Zewdu S. Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. PLoS One 2019;14:e0211688. [PMID: 30716126 DOI: 10.1371/journal.pone.0211688] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Mwangi PM, Wamalwa D, Marangu D, Obimbo EM, Ng'ang'a M. Implementation of Isoniazid Preventive Therapy Among HIV-Infected Children at Health Facilities in Nairobi County, Kenya: A Cross-Sectional Study. East Afr Health Res J 2019;3:141-50. [PMID: 34308207 DOI: 10.24248/EAHRJ-D-19-00005] [Reference Citation Analysis]
46 Dodd PJ, Pretorius C, Williams BG. Modelling the HIV-Associated TB Epidemic and the Impact of Interventions Aimed at Epidemic Control. HIV and Tuberculosis 2019. [DOI: 10.1007/978-3-030-29108-2_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Takarinda KC, Choto RC, Mutasa-Apollo T, Chakanyuka-Musanhu C, Timire C, Harries AD. Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice? Public Health Action 2018;8:218-24. [PMID: 30775283 DOI: 10.5588/pha.18.0051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
48 Saraceni V, Benzaken AS, Pereira GFM, Andrade KB, Oliveira PB, Arakaki-Sanchez D, Caruso A, Souza FMA. Tuberculosis burden on AIDS in Brazil: A study using linked databases. PLoS One 2018;13:e0207859. [PMID: 30462733 DOI: 10.1371/journal.pone.0207859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
49 Surie D, Borgdorff MW, Cain KP, Click ES, DeCock KM, Yuen CM. Assessing the impact of antiretroviral therapy on tuberculosis notification rates among people with HIV: a descriptive analysis of 23 countries in sub-Saharan Africa, 2010-2015. BMC Infect Dis 2018;18:481. [PMID: 30257667 DOI: 10.1186/s12879-018-3387-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
50 Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV-no more excuses. Lancet Glob Health 2017;5:e1048-9. [PMID: 29025618 DOI: 10.1016/S2214-109X(17)30390-X] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
51 Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM, Hanekom WA, Mahomed H, McShane H, Hatherill M. Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. Int J Tuberc Lung Dis 2017;21:778-83. [PMID: 28633702 DOI: 10.5588/ijtld.16.0709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis 2017;21:537-43. [PMID: 28399969 DOI: 10.5588/ijtld.16.0775] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
53 Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ 2017;5:e4165. [PMID: 29259846 DOI: 10.7717/peerj.4165] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
54 Maniewski U, Payen MC, Delforge M, De Wit S. Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting? Acta Clin Belg 2017;72:238-41. [PMID: 27686180 DOI: 10.1080/17843286.2016.1237696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
55 Karo B, Krause G, Castell S, Kollan C, Hamouda O, Haas W; ClinSurv HIV Study Group. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis 2017;17:517. [PMID: 28743248 DOI: 10.1186/s12879-017-2627-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
56 Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 2016;72:572-8. [PMID: 27049511 DOI: 10.1097/QAI.0000000000001018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
57 da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Grinsztejn E, da Silva Lourenço MC, Grinsztejn B, Veloso VG. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death. BMC Infect Dis 2017;17:373. [PMID: 28558689 DOI: 10.1186/s12879-017-2473-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
58 Lahey T, von Reyn CF. Mycobacterium bovisBCG and New Vaccines for the Prevention of Tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch11] [Reference Citation Analysis]
59 Haley CA. Treatment of Latent Tuberculosis Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch6] [Reference Citation Analysis]
60 Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch34] [Reference Citation Analysis]
61 Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch Hospital, Ethiopia. Ther Clin Risk Manag 2017;13:361-6. [PMID: 28392698 DOI: 10.2147/TCRM.S127765] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
62 Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Health Action 2017;7:55-60. [PMID: 28775944 DOI: 10.5588/pha.16.0102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
63 Salazar-austin N, Jain S, Dooley KE. Management of Tuberculosis in Special Populations. Handbook of Tuberculosis 2017. [DOI: 10.1007/978-3-319-26273-4_6] [Reference Citation Analysis]
64 Dowdy DW, Golub JE. Public Health Issues. Handbook of Tuberculosis 2017. [DOI: 10.1007/978-3-319-26273-4_5] [Reference Citation Analysis]
65 Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 2016;11:e0165614. [PMID: 27906986 DOI: 10.1371/journal.pone.0165614] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
66 Takarinda KC, Harries AD, Sandy C, Mutasa-Apollo T, Zishiri C. Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in Zimbabwe. Public Health Action 2016;6:164-8. [PMID: 27695678 DOI: 10.5588/pha.16.0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
67 Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis 2016;20:85-92. [PMID: 26688533 DOI: 10.5588/ijtld.15.0391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
68 Saito S, Mpofu P, Carter EJ, Diero L, Wools-Kaloustian KK, Yiannoutsos CT, Beverly MS, Tsiouris S, Somi GR, Ssali J, Nash D, Elul B. Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012. J Acquir Immune Defic Syndr 2016;71:e96-e106. [PMID: 26910387 DOI: 10.1097/QAI.0000000000000896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
69 Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016;30:1607-15. [PMID: 27243774 DOI: 10.1097/QAD.0000000000001098] [Cited by in Crossref: 92] [Cited by in F6Publishing: 101] [Article Influence: 15.3] [Reference Citation Analysis]
70 Bortz M, Kano M, Ramroth H, Barcellos C, Weaver SR, Rothenberg R, Magalhães M. Disaggregating health inequalities within Rio de Janeiro, Brazil, 2002-2010, by applying an urban health inequality index. Cad Saude Publica 2015;31 Suppl 1:107-19. [PMID: 26648367 DOI: 10.1590/0102-311X00081214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
71 Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, White RG. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS 2016;30:1279-86. [PMID: 26950316 DOI: 10.1097/QAD.0000000000001078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
72 Alemu YM, Awoke W, Wilder-Smith A. Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. BMJ Open 2016;6:e009058. [PMID: 27084271 DOI: 10.1136/bmjopen-2015-009058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
73 Coelho LE, Cardoso SW, Amancio RT, Moreira RI, Ribeiro SR, Coelho AB, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infect Dis 2016;16:134. [PMID: 27001753 DOI: 10.1186/s12879-016-1462-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
74 Harries AD, Kumar AM, Kyaw NTT, Hoa NB, Takarinda KC, Zachariah R. The role of antiretroviral therapy in reducing TB incidence and mortality in high HIV-TB burden countries. Asian Pacific Journal of Tropical Disease 2016;6:243-247. [DOI: 10.1016/s2222-1808(15)61023-4] [Reference Citation Analysis]
75 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
76 Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, Waldrop G, Kranzer K, Doherty M, Getahun H. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc 2016;19:20714. [PMID: 26765347 DOI: 10.7448/IAS.19.1.20714] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 11.8] [Reference Citation Analysis]
77 Hopewell PC, Kato-maeda M, Ernst JD. Tuberculosis. Murray and Nadel's Textbook of Respiratory Medicine 2016. [DOI: 10.1016/b978-1-4557-3383-5.00035-x] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
78 Kanyerere H, Harries AD, Tayler-Smith K, Jahn A, Zachariah R, Chimbwandira FM, Mpunga J. The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy. Trop Med Int Health 2016;21:101-7. [PMID: 26509352 DOI: 10.1111/tmi.12630] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
79 Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
80 Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015;386:2344-53. [PMID: 26515679 DOI: 10.1016/S0140-6736(15)00323-2] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 16.7] [Reference Citation Analysis]
81 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
82 Azadi M, Bishai DM, Dowdy DW, Moulton LH, Cavalcante S, Saraceni V, Pacheco AG, Cohn S, Chaisson RE, Durovni B, Golub JE. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study. Int J Tuberc Lung Dis 2014;18:1443-8. [PMID: 25517809 DOI: 10.5588/ijtld.14.0108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
83 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
84 Ayele HT, van Mourik MS, Bonten MJ. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infect Dis 2015;15:334. [PMID: 26269094 DOI: 10.1186/s12879-015-1089-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
85 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
86 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
87 Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, Corbett EL, Churchyard GJ, Grant AD, White RG. Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol 2015;181:619-32. [PMID: 25792607 DOI: 10.1093/aje/kwu320] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
88 Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health 2015;15:346. [PMID: 25886730 DOI: 10.1186/s12889-015-1719-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
89 Barletta F, Otero L, de Jong BC, Iwamoto T, Arikawa K, Van der Stuyft P, Niemann S, Merker M, Uwizeye C, Seas C, Rigouts L. Predominant Mycobacterium tuberculosis Families and High Rates of Recent Transmission among New Cases Are Not Associated with Primary Multidrug Resistance in Lima, Peru. J Clin Microbiol 2015;53:1854-63. [PMID: 25809979 DOI: 10.1128/JCM.03585-14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
90 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015;29:351-9. [PMID: 25686683 DOI: 10.1097/QAD.0000000000000535] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
91 Kufa T, Mabuto T, Muchiri E, Charalambous S, Rosillon D, Churchyard G, Harris RC. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014;9:e111209. [PMID: 25393281 DOI: 10.1371/journal.pone.0111209] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
92 Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, Pacheco AG, Chaisson RE, Durovni B. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr 2014;66:552-8. [PMID: 24853308 DOI: 10.1097/QAI.0000000000000219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
93 Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9:e104557. [PMID: 25105417 DOI: 10.1371/journal.pone.0104557] [Cited by in Crossref: 41] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
94 Cheng MP, Hirji A, Roth DZ, Cook VJ, Lima VD, Montaner JS, Johnston JC. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. Can J Public Health 2014;105:e258-62. [PMID: 25166127 DOI: 10.17269/cjph.105.4260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
95 Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682–690. [PMID: 24835842 DOI: 10.1016/s0140-6736(14)60162-8] [Cited by in Crossref: 161] [Cited by in F6Publishing: 180] [Article Influence: 20.1] [Reference Citation Analysis]
96 Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L; German ClinSurv HIV Study Group. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014;14:148. [PMID: 24646042 DOI: 10.1186/1471-2334-14-148] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
97 Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice FL. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Depend 2014;134:106-14. [PMID: 24128379 DOI: 10.1016/j.drugalcdep.2013.09.020] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
98 Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG. Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis. PLoS One 2013;8:e75466. [PMID: 24069418 DOI: 10.1371/journal.pone.0075466] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
99 Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013;13:852-8. [PMID: 23954450 DOI: 10.1016/S1473-3099(13)70187-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 8.4] [Reference Citation Analysis]
100 Addis Alene K, Nega A, Wasie Taye B. Incidence and predictors of tuberculosis among adult people living with human immunodeficiency virus at the University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis 2013;13:292. [PMID: 23806088 DOI: 10.1186/1471-2334-13-292] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
101 Kibret KT, Yalew AW, Belaineh BG, Asres MM. Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. PLoS One 2013;8:e64488. [PMID: 23762214 DOI: 10.1371/journal.pone.0064488] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
102 Batista Jd, de Albuquerque Mde F, Maruza M, Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One 2013;8:e63916. [PMID: 23675515 DOI: 10.1371/journal.pone.0063916] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
103 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
104 Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One 2013;8:e55824. [PMID: 23418463 DOI: 10.1371/journal.pone.0055824] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
105 Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
106 Kerkhoff AD, Kranzer K, Samandari T, Nakiyingi-Miiro J, Whalen CC, Harries AD, Lawn SD. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS One 2012;7:e49928. [PMID: 23209621 DOI: 10.1371/journal.pone.0049928] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
107 Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012;26:2121-33. [PMID: 22695302 DOI: 10.1097/QAD.0b013e3283565dd1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
108 Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. [PMID: 22905358 DOI: 10.7448/ias.15.2.17396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
109 Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S136-44. [PMID: 22797735 DOI: 10.1097/QAI.0b013e31825cfe8e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
110 Lahey T, Mackenzie T, Arbeit RD, Bakari M, Mtei L, Matee M, Maro I, Horsburgh CR, Pallangyo K, von Reyn CF. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013;56:151-8. [PMID: 22972862 DOI: 10.1093/cid/cis798] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
111 Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 239] [Cited by in F6Publishing: 262] [Article Influence: 23.9] [Reference Citation Analysis]
112 Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156. [PMID: 22479548 DOI: 10.1371/journal.pone.0034156] [Cited by in Crossref: 133] [Cited by in F6Publishing: 150] [Article Influence: 13.3] [Reference Citation Analysis]
113 del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012;54:1364-72. [PMID: 22460971 DOI: 10.1093/cid/cis203] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
114 Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res 2011;9:383-92. [PMID: 21999773 DOI: 10.2174/157016211798038524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
115 Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, Phanuphak N, Buajoom R, Suwanmala P, Phanuphak P. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. AIDS Res Hum Retroviruses 2012;28:270-5. [PMID: 21899431 DOI: 10.1089/aid.2011.0041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
116 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
117 Moore DM, Yiannoutsos CT, Musick BS, Tappero J, Degerman R, Campbell J, Were W, Kaharuza F, Alexander LN, Downing R, Mermin J. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2011;58:289-96. [PMID: 21857358 DOI: 10.1097/QAI.0b013e3182303716] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
118 Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-81. [PMID: 21756508 DOI: 10.5588/ijtld.10.0483] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
119 Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc 2011;8:288-93. [PMID: 21653530 DOI: 10.1513/pats.201010-064WR] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
120 Moura LC, Ximenes RA, Ramos HL, Miranda Filho DB, Freitas CD, Silva RM, Coimbra I, Batista Jd, Montarroyos UR, Militão Albuquerque Mde F. An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health 2011;11:687. [PMID: 21892936 DOI: 10.1186/1471-2458-11-687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011;9:415-30. [PMID: 21504399 DOI: 10.1586/eri.11.21] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
122 Date AA, Miller B. Antiretroviral therapy and tuberculosis: what's the connection and what's the way forward? J Acquir Immune Defic Syndr 2011;57:255-7. [PMID: 21602692 DOI: 10.1097/QAI.0b013e31822204fa] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Tan DB, Lim A, Yong YK, Ponnampalavanar S, Omar S, Kamarulzaman A, French MA, Price P. TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. AIDS 2011;25:1455-60. [PMID: 21610488 DOI: 10.1097/QAD.0b013e328348fb18] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
124 Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011;56:349-55. [PMID: 20926954 DOI: 10.1097/QAI.0b013e3181f9fb39] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
125 Dalhoff K, Rupp J. Bedrohung durch die HIV/Tuberkulose-Koinfektion. Pneumologe 2011;8:32-39. [DOI: 10.1007/s10405-010-0402-5] [Reference Citation Analysis]
126 Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183:1103-1111. [PMID: 21148723 DOI: 10.1164/rccm.201004-0620oc] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
127 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24 Suppl 5:S57-65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 62] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]
128 Grant AD, Fielding KL, Charalambous S, Chaisson RE, Churchyard GJ. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood? AIDS 2010;24 Suppl 5:S15-8. [PMID: 21079423 DOI: 10.1097/01.aids.0000391011.40892.ff] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
129 Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS 2010;24 Suppl 5:S49-56. [PMID: 21079428 DOI: 10.1097/01.aids.0000391022.95412.a6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
130 Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 Suppl 5:S5-13. [PMID: 21079429 DOI: 10.1097/01.aids.0000391010.02774.6f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
131 Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE. Isoniazid preventive therapy for HIV-infected people: evidence to support implementation. AIDS 2010;24 Suppl 5:S1-3. [PMID: 21079422 DOI: 10.1097/01.aids.0000391009.95149.ec] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
132 Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 2010;107:19485-9. [PMID: 20974976 DOI: 10.1073/pnas.1005660107] [Cited by in Crossref: 60] [Cited by in F6Publishing: 71] [Article Influence: 5.0] [Reference Citation Analysis]
133 Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011;2011:980594. [PMID: 20936108 DOI: 10.1155/2011/980594] [Cited by in Crossref: 42] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
134 Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010;10:267. [PMID: 20840743 DOI: 10.1186/1471-2334-10-267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
135 Naidoo K, Naidoo K, Padayatchi N, Abdool Karim Q. HIV-Associated Tuberculosis. Clin Dev Immunol 2011;2011:585919. [PMID: 20871843 DOI: 10.1155/2011/585919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
136 Jassal MS, Bishai WR. Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis 2010;50 Suppl 3:S156-64. [PMID: 20397943 DOI: 10.1086/651486] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
137 Miranda AE, Golub JE, Lucena Fde F, Maciel EN, Gurgel Mde F, Dietze R. Tuberculosis and AIDS co-morbidity in Brazil: linkage of the tuberculosis and AIDS databases. Braz J Infect Dis 2009;13:137-41. [PMID: 20140359 DOI: 10.1590/s1413-86702009000200013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
138 Caminero JA. ¿Podemos mejorar la prevención de la tuberculosis? Enfermedades Infecciosas y Microbiología Clínica 2010;28:211-214. [DOI: 10.1016/j.eimc.2009.12.004] [Reference Citation Analysis]
139 von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, Horsburgh CR, Pallangyo K; DarDar Study Group. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010;24:675-85. [PMID: 20118767 DOI: 10.1097/QAD.0b013e3283350f1b] [Cited by in Crossref: 167] [Cited by in F6Publishing: 174] [Article Influence: 13.9] [Reference Citation Analysis]
140 Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010;5:18-26. [PMID: 20046144 DOI: 10.1097/COH.0b013e328333850f] [Cited by in Crossref: 75] [Cited by in F6Publishing: 84] [Article Influence: 6.3] [Reference Citation Analysis]
141 Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009;30:685-99, viii. [PMID: 19925961 DOI: 10.1016/j.ccm.2009.08.010] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
142 Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, Fine PE, Glynn JR. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010;24:417-26. [PMID: 20042847 DOI: 10.1097/QAD.0b013e32832f51cf] [Cited by in Crossref: 78] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
143 Etard JF, Diouf A, De Beaudrap P, Akoi K, Ngom-Guèye NF, Ndiaye I, Ecochard R, Sow PS, Eric D. Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J 2009;3:63-70. [PMID: 20148061 DOI: 10.2174/1874613600903010063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
144 Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009;23:2507-15. [PMID: 19770622 DOI: 10.1097/QAD.0b013e3283320dfd] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
145 Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88:253-259. [PMID: 20431788 DOI: 10.2471/blt.09.066522] [Cited by in Crossref: 50] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
146 Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-25. [PMID: 19461502 DOI: 10.1097/QAD.0b013e32832d3b6d] [Cited by in Crossref: 224] [Cited by in F6Publishing: 246] [Article Influence: 17.2] [Reference Citation Analysis]
147 Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009;4:325-33. [PMID: 19532072 DOI: 10.1097/COH.0b013e32832c7d61] [Cited by in Crossref: 107] [Cited by in F6Publishing: 126] [Article Influence: 8.2] [Reference Citation Analysis]
148 Wilkinson KA, Seldon R, Meintjes G, Rangaka MX, Hanekom WA, Maartens G, Wilkinson RJ. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009;180:674-83. [PMID: 19628776 DOI: 10.1164/rccm.200904-0568OC] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
149 Wood R, Lawn SD, Bekker LG. Are the effects of isoniazid preventive therapy and highly active antiretroviral therapy additive in preventing HIV-associated tuberculosis? AIDS 2009;23:1444-6. [PMID: 19564724 DOI: 10.1097/QAD.0b013e32832d53e7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
150 Golub JE, Chaisson RE, Martinson NA. Additive effects of isoniazid preventive therapy and HAART. AIDS 2009;23:1446-7. [PMID: 19564725 DOI: 10.1097/QAD.0b013e32832d53fc] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
151 Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, Merati TP, Pujari S, Chen YM, Phanuphak P, Vonthanak S, Sirisanthana T, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang F, Tau G, Ditangco R. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 2009;9:46. [PMID: 19383122 DOI: 10.1186/1471-2334-9-46] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
152 Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 2008;49:532-7. [PMID: 18989223 DOI: 10.1097/QAI.0b013e31818d5c1c] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
153 Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-6. [PMID: 19525621 DOI: 10.1097/QAD.0b013e328327964f] [Cited by in Crossref: 159] [Cited by in F6Publishing: 172] [Article Influence: 12.2] [Reference Citation Analysis]
154 Hoffmann CJ, Chaisson RE. HIV/AIDS and Opportunistic Illnesses. Manson's Tropical Diseases 2009. [DOI: 10.1016/b978-1-4160-4470-3.50024-0] [Reference Citation Analysis]
155 Pacheco AG, Saraceni V, Tuboi SH, Moulton LH, Chaisson RE, Cavalcante SC, Durovni B, Faulhaber JC, Golub JE, King B, Schechter M, Harrison LH. Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil. Am J Epidemiol 2008;168:1326-32. [PMID: 18849301 DOI: 10.1093/aje/kwn249] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
156 Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008;22:2527-33. [PMID: 19005276 DOI: 10.1097/QAD.0b013e328311ac4e] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
157 Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22:1897-908. [PMID: 18784453 DOI: 10.1097/QAD.0b013e32830007cd] [Cited by in Crossref: 450] [Cited by in F6Publishing: 505] [Article Influence: 32.1] [Reference Citation Analysis]
158 Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 2008;3:e3132. [PMID: 18781195 DOI: 10.1371/journal.pone.0003132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
159 Pontier S. Le poumon du sujet infecté par le VIH. Revue des Maladies Respiratoires 2008;25:53-57. [DOI: 10.1016/s0761-8425(08)74078-6] [Reference Citation Analysis]
160 Davis JL, Fei M, Huang L. Respiratory infection complicating HIV infection. Curr Opin Infect Dis 2008;21:184-90. [PMID: 18317044 DOI: 10.1097/QCO.0b013e3282f54fff] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
161 Hoffmann CJ, Mills LA, Gallant JE. Future of HIV/AIDS Care in Low- and Middle- Income Countries. Public Health Aspects of HIV/AIDS in Low and Middle Income Countries 2008. [DOI: 10.1007/978-0-387-72711-0_3] [Reference Citation Analysis]